UIC Director for both Primacy and Direct Implementation programs already had the authority to require that this or any other log be run if he/she deemed it necessary in evaluating underground injection operations to assure non-endangerment to USDWs (40 CFR 144.27). The intent and responsibility inherent in this established authority are independent of the approval of this alternative MIT methodology. Therefore, EPA continues to believe that the OA log should be approved as an alternative MIT. EPA solicits any comments or data that may affect the conclusions stated here.

II. Special Conditions

A. Limitations for Conducting the Oxygen Activation Method Mechanical Integrity Test

As previously mentioned, extensive testing and evaluation of this logging technique has been conducted by the EPA. Based upon this analysis, the following are prescribed limitations for conducting the Oxygen Activation Method mechanical integrity test:

(1) The Oxygen Activation Method has only been perfected by a limited number of commercial geophysical logging companies. Only those companies providing logging tools capable of detecting flow velocities of at least three (3) feet per minute shall be employed in demonstrating mechanical integrity pursuant to 40 CFR 146.8(a)(2). Individual UIC Directors can supply interested parties with a list of companies that provide acceptable OA logging services.

(2) Determination of injection zone isolation and/or fluid flow behind the pipe (i.e., flow that is not directly related to injection) will require that readings be taken at a minimum of three stations. Three readings lasting at least 5 minutes shall be taken at each stationary position. This procedure allows enough information to be gathered so that more precise results will be obtained. In some cases where results are inconclusive, additional readings over longer time periods may be required by the UIC Director. If the repeat measurements are identical or within the normal range of statistical error for the tool then the measurement shall be accepted as accurate and valid.

(3) Demonstration of injection zone isolation also will require that the three stations be located far enough above the top of the injection zone (at least 10 feet) that turbulence does not affect the readings. All readings should be taken with the well injecting fluid at the normal rate. The injection should be continuous with minimum rate and pressure fluctuations.

(4) Determination of flow behind the pipe will require that the stations be located at the base of each USDW, adjacent to the confining layer which isolates injection fluid from the injection zone, and at some point between the two locations.

(5) If any significant flow indication (e.g., >3 ft./minute) is observed, the well shall fail the test (i.e., it does not establish mechanical integrity pursuant to requirements stated in 40 CFR 146.8(a)(2)).

(6) The Oxygen Activation Method shall not be used in wells with pipe diameters less than $1^{1}\frac{1}{16}$ inches (inside diameter).

(7) The Oxygen Activation Method shall be used only for pipe diameters up to $13\frac{3}{8}$ inches (inside diameter).

B. Determination

The Oxygen Activation Method, subject to the conditions and procedures discussed in this notice, provides the necessary information to demonstrate reliably whether a well has significant fluid movement through vertical channels adjacent to the well bore.

Subject to receipt and consideration of comments and referenced data, EPA is proposing to reapprove this test as an effective alternative mechanical integrity test for well Classes I through V in all States.

Dated: September 10, 1991.

James R. Elder,

Director, Office of Ground Water and Drinking Water.

[FR Doc. 91-22625 Filed 9-18-91; 8:45 am]

BILLING CODE 6560-50-M

[FRL-4010-5]

Underground Injection Control Program; Hazardous Waste Disposal Injection Restrictions; Petition for Exemption—Class I Hazardous Waste Injection; E.I. du Pont de Nemours

AGENCY: Environmental Protection Agency.

ACTION: Notice of final decision on petition.

SUMMARY: Notice is hereby given that an exemption to the land disposal restrictions under the 1984 Hazardous and Solid Waste Amendments to the Resource Conservation and Recovery Act has been granted to E.I. du Pont de Nemours, for the Class I injection wells located at Orange, Texas. As required by 40 CFR part 148, the company has adequately demonstrated to the satisfaction of the Environmental Protection Agency by petition and supporting documentation that, to a reasonable degree of certainty, there will be no migration of hazardous constituents from the injection zone for as long as the waste remains hazardous. This final decision allows the underground injection by E.I. du Pont de Nemours, of the specific restricted hazardous waste identified in the petition, into the Class I hazardous waste injection wells at the Orange, Texas facility specifically identified in the petition, for as long as the basis for granting an approval of the petition remains valid, under provisions of 40 CFR 148.24. As required by 40 CFR 124.10, a public notice was issued July 5, 1991. A public hearing was held August 7, 1991, and a public comment period ended on August 19, 1991. All comments have been addressed and have been considered in the final decision. This decision constitutes final Agency action and there is no Administrative appeal.

DATES: This action is effective as of September 10, 1991.

ADDRESSES: Copies of the petition and all pertinent information relating thereto are on file at the following location: Environmental Protection Agency, Region 6, Water Management Division, Water Supply Branch (6W-SU), 1445 Ross Avenue, Dallas, Texas 75202-2733.

FOR FURTHER INFORMATION CONTACT: Oscar Cabra, Jr., Chief Water Supply Branch, EPA—Region 6, telephone (214) 655-7110, (FTS) 255-7110.

Myron O. Knudson,

Director, Water Management Division (6W).

[FR Doc. 91-22628 Filed 9-18-91; 8:45 am]

BILLING CODE 6560-50-M

[OPP-00309; FRL-3948-4]

State FIFRA Issues Research and Evaluation Group (SFIREG); Working Committee on Groundwater Protection and Pesticide Disposal; Open Meeting

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: The State FIFRA Issues Research and Evaluation Group (SFIREG) Working Committee on Groundwater Protection and Pesticide Disposal will hold a 2-day meeting, beginning on September 26, 1991, and ending on September 27, 1991. This notice announces the location and times for the meeting and sets forth tentative agenda topics. The meeting is open to the public.

DATES: The SFIREG Working Committee will meet on Thursday, September 26, 1991, from 8:30 a.m. to 5 p.m., and on Friday, September 27, 1991, beginning at 8:30 a.m. and adjourning at approximately 1 p.m.

ADDRESSES: The meeting will be held at: Days Hotel - Crystal City, 2000 Jefferson Davis Highway, Arlington, VA, (703) 920–8600.

FOR FURTHER INFORMATION CONTACT: By mail: Arty Williams, Office of Pesticide Programs (H7506C), Environmental Protection Agency, 401 M St., SW., Washington, DC 20460. Office location and telephone number: Rm. 1100E, Crystal Mall No. 2, 1921 Jefferson Davis Highway, Arlington, VA, (703) 557–7371.

SUPPLEMENTARY INFORMATION: The tentative agenda includes the following:

1. Final Ground Water Task Force Report and its impact on FY '93 cooperative agreement guidance.
2. Pesticides and Ground Water Strategy status report.
3. State Management Plan guidance and support documents discussion.
4. Status report on the Phase 2 Report of the National Pesticides in Drinking Water Survey.
4. Proposed Ground Water Restricted Use Rule.
5. Report of the Senior Pesticide Officials' Ground Water Course.
6. Discussion of the draft report from the SFIREG pesticide mixing/loading site survey.
7. Wetlands definition discussion.
8. FIFRA section 19 disposal regulations.
9. State pesticide disposal projects and discussion of problems, solutions and RCRA implications.
10. Definitions and issues related to pesticide vs. waste in the wood preservative area.
11. University of Illinois and Ciba Geigy's report on a developmental mobile pesticide container incinerator.
12. State reports on initiatives related to ground water protection and pesticide disposal.
13. Other topics as appropriate.

Dated: September 12, 1991.

Douglas D. Campt,

Director, Office of Pesticide Programs.

[FR Doc. 91–22572 Filed 9–18–91; 8:45 am]

BILLING CODE 6560–50–F

FEDERAL MARITIME COMMISSION

Port of Oakland/Mitsui O.S.K. Lines Terminal Agreement; Agreement(s) Filed

The Federal Maritime Commission hereby gives notice of the filing of the following agreement(s) pursuant to section 5 of the Shipping Act of 1984.

Interested parties may inspect and obtain a copy of each agreement at the Washington, DC Office of the Federal Maritime Commission, 1100 L Street, NW., room 10325. Interested parties may submit comments on each agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, within 10 days after the date of the **Federal Register** in which this notice appears. The requirements for comments are found in § 572.603 of title 46 of the Code of Federal Regulations. Interested persons should consult this section before communicating with the Commission regarding a pending agreement.

Agreement No.: Agreement No. 224–20563.

Title: Port of Oakland/Mitsui O.S.K. Lines Terminal Agreement.

Parties: City of Oakland ("Port") Mitsui O.S.K. Lines, Ltd. ("Mitsui").

Synopsis: The proposed Agreement filed September 6, 1991, would permit Mitsui to lease certain assigned premises in the Port's Seventh Street Marine Terminal area on a nonexclusive preferential basis for use as a containership terminal. The Agreement has an initial term of twenty-five years.

By Order of the Federal Maritime Commission.

Dated: September 13, 1991.

Joseph C. Polking,

Secretary.

[FR Doc. 91–22537 Filed 9–18–91; 8:45 am]

BILLING CODE 6730–01–M

South Louisiana Port Commission/ Occidental Chemical Corporation Terminal Lease Agreement; Agreement(s) Filed

The Federal Maritime Commission hereby gives notice that the following agreement(s) has been filed with the Commission pursuant to section 15 of the Shipping Act, 1916, and section 5 of the Shipping Act of 1984.

Interested parties may inspect and obtain a copy of each agreement at the Washington, DC Office of the Federal Maritime Commission, 1100 L Street, NW., room 10325. Interested parties may submit protests or comments on each agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, within 10 days after the date of the **Federal Register** in which this notice appears. The requirements for comments and protests are found in § 560.7 and/or § 572.603 of title 46 of the Code of Federal Regulations. Interested persons should consult this section before communicating with the Commission regarding a pending agreement.

Any person filing a comment or protest with the Commission shall, at the same time, deliver a copy of that document to the person filing the agreement at the address shown below.

Agreement No.: 224–003969–003.

Title: South Louisiana Port Commission/Occidental Chemical Corporation Terminal Lease Agreement.

Parties: South Louisiana Port Commission (Port Commission) Occidental Chemical Corporation (Petroleum).

Filing Party: Milton J. Stickles, Jr., Esq. Cadwalader, Wickersham & Taft 1333 New Hampshire Avenue, NW., Washington, DC 20036

Synopsis: Agreement No. 224–003969–003, designated as "The Amended Lease", revises and restates a lease agreement and amendments nos. 1 and 2 thereto that were filed with the Federal Maritime Commission as Agreements No. T–3969, T–3969–1 and T–3969–2 and approved by Commission Order dated June 25, 1981. The Amended Lease covers terminal facilities located in St. Charles Parish, Louisiana. The facilities will be used by Lessee and other common and contract carriers in interstate and foreign commerce in the loading and unloading of vessels and storage of ammonia and other compatible products. Lessee and Lessor are amending the original 1981 agreement in order to provide for the lease of the facilities to Lessee (which is the successor to the original lessee, Hooker Chemical Properties Corporation) and payment by the Lessee of rental payments in an amount sufficient to timely pay the principal of premium, if any, and interest on revenue bonds and other amounts due.

Agreement No. 224–003969–003 is filed under both section 15 of the Shipping Act, 1916 and section 5 of the Shipping Act of 1984.

Agreement No.: 224–003969–004.

Title: South Louisiana Port Commission and Occidental Petroleum Corporation (Petroleum) Lease Guaranty Agreement.

Parties: South Louisiana Port Commission (Port Commission) Occidental Petroleum Corporation (Petroleum).

Filing Party: Milton J. Stickles, Jr., Esq. Cadwalader, Wickerson & Taft 1333 New Hampshire Avenue, NW., Washington, DC 20036

Synopsis: Agreement No. 224–003969–004, designated as a Lease Guaranty Agreement (Guaranty Agreement) obligates Petroleum to perform the agreements and obligations of

Occidental Chemical Corporation (Chemical) under the Amended and Restated Lease Agreement (Amended Lease) between Port Commission and Chemical (Agreement No 224-003969-003) in the event of Chemical's default or non performance of the Amended Lease

Agreement No 224-003969-004 is filed under both section 15 of the Shipping Act, 1916 and section 5 of the Shipping Act of 1984

By Order of the Federal Maritime Commission

Dated: September 12, 1991

Joseph C. Polking,

Secretary

[FR Doc. 91-22538 Filed 9-18-91, 8:45 am]

BILLING CODE 6730-01-M

GOVERNMENT PRINTING OFFICE

Depository Library Council to the Public Printer; Meeting

The Depository Library Council to the Public Printer will meet October 22-23, 1991, at the U.S. Government Printing Office (GPO), in the Carl Hayden Room, 732 North Capitol Street NW., Washington, DC 20401.

The purpose of this meeting is to discuss the Depository Library Program.

The meeting is open to the public. Anyone who wishes to attend should notify John Tate, U.S. Government Printing Office (SL), Washington, DC 20401. Telephone: (202) 275-1109. A limited number of hotel rooms have been reserved at the Quality Inn Hotel on Capitol Hill, 415 New Jersey Avenue NW., Washington, DC 20001, for anyone needing hotel accommodations. Telephone: (202) 638-1616. Room cost per night is $85.00.

Dated: September 10, 1991.

Robert W. Houk,

Public Printer.

[FR Doc. 91-22524 Filed 9-18-91; 8:45 am]

BILLING CODE 1505-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 91F-0339]

Betz Laboratories, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Betz Laboratories, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 2 bromo 2 nitro 1,3 propanediol as an antimicrobial/ preservative in fillers, binders, pigment slurries, sizings, and coatings used in the manufacture of paper and paperboard articles intended for food contact use

FOR FURTHER INFORMATION CONTACT: Richard H. White, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 1B4279) has been filed by Betz Laboratories, Inc, 4636 Somerton Rd., Trevose, PA 19053. The petition proposes to amend the food additive regulations in § 176.170 *Components of paper and paperboard in contact with aqueous and fatty foods* (21 CFR 176.170) to provide for the safe use of 2-bromo-2-nitro-1,3-propanediol as an antimicrobial/preservative in fillers, binders, pigment slurries, sizings, and coatings used in the manufacture of paper and paperboard articles intended for food-contact use.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: September 9, 1991.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91-22640 Filed 9-18-91; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91F-0287]

Henkel Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Henkel Corp. has filed a petition proposing that the food additive regulations be amended to change the melting point range from "49°C to 52°C" to "55°C to 58°C" and to revise the identity description for the additive pentaerythritol adipate stearate to indicate that it is an ester of pentaerythritol with adipic acid and stearic acid plus its associated acids (chiefly palmitic) having 14 percent adipic acid and 71 percent stearic acid and its associated acids

FOR FURTHER INFORMATION CONTACT: Julius Smith, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 1B4270), has been filed by Henkel Corp., 300 Brookside Ave., Ambler, PA 19002. The petition proposes to amend the food additive regulations in § 178.3690 *Pentaerythritol adipate-stearate* (21 CFR 178.3690) to change the melting point range from "49°C to 52°C" to "55°C to 58°C" and to revise the identity description for the additive pentaerythritol adipate-stearate to indicate that it is an ester of pentaerythritol with adipic acid and stearic acid plus its associated acids (chiefly palmitic) having 14 percent adipic acid and 71 percent stearic acids and its associated acids.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: September 9, 1991.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91-22641 Filed 9-18-91; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91F-0328]

Yoshitomi Pharmaceutical Industries, LTD.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Yoshitomi Pharmaceutical Industries, Ltd., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 4,5-dicloro-1,2-dithiol-3-

one as a slimicide in the manufacture of paper and paperboard articles intended to contact food.

FOR FURTHER INFORMATION CONTACT: Richard H. White, Center for Food Safety and Applied Nutrition (HFF–335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–472–5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 1B4275) has been filed by Yoshitomi Pharmaceutical Industries, Ltd., c/o suite 1000, 1625 K St. NW., Washington, DC 20006–1604. The petition proposes to amend the food additive regulations in § 176.300 *Slimicides* (21 CFR 176.300) to provide for the safe use of 4,5-dicloro-1,2-dithiol-3-one as a slimicide in the manufacture of paper and paperboard articles intended to contact food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: September 9, 1991.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91–22642 Filed 9–18–91; 8:45 am]

BILLING CODE 4160–01–M

Advisory Committees; Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

MEETINGS: The following advisory committee meetings are announced:

Ophthalmic Devices Panel of the Medical Devices Advisory Committee

Date, time, and place. October 4, 1991, 9 a.m., First Floor Auditorium, Hubert H. Humphrey Bldg., 200 Independence Ave. SW., Washington, DC.

Type of meeting and contact person. Open public hearing, 9 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 3 p.m.; closed committee deliberations, 3 p.m. to 4 p.m.; open committee discussion, 4 p.m. to 5 p.m.; Daniel W. C. Brown, Center for Devices and Radiological Health (HFZ–460), Food and Drug Administration, 1390 Piccard Dr., Rockville, MD 20850, 301–427–1080.

General functions of the committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational devices and makes recommendations for their regulation.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before September 20, 1991, and submit a brief statement of the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss general issues relating to approvals of premarket approval applications (PMA's) for contact lenses, intraocular lenses, and other class III surgical or diagnostic devices, and may discuss specific PMA's for these devices.

Closed committee deliberations. The committee may discuss trade secret and/or confidential commercial information relevant to PMA's for contact lenses, intraocular lenses, and surgical or diagnostic devices. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

Peripheral and Central Nervous System Drugs Advisory Committee

Date, time, and place. October 24 and 25, 1991, 8 a.m., Conference Rms. D and E, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD.

Type of meeting and contact person. Open public hearing, October 24, 1991, 8 a.m. to 9 a.m., unless public participation does not last that long; closed committee deliberations, 9 a.m. to 5 p.m.; open public hearing, October 25, 1991, 8 a.m. to 9 a.m., unless public participation does not last that long; open committee discussion, 9 a.m. to 5 p.m.; Michael A. Bernstein, Center for Drug Evaluation and Research (HFD–120), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–4020.

General function of the committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in neurological diseases.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before October 17, 1991, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. On October 25, 1991, the committee will discuss IMIGRAN Injectable (Sumatriptan Injectable), new drug application 20–080, Glaxo, Inc., for use in the treatment of migraine.

Closed committee deliberations. On October 24, 1991, the committee will discuss trade secret and/or confidential commercial information relevant to a pending investigational new drug application. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

Each public advisory committee meeting listed above may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. The dates and times reserved for the separate portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative